Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|February 3, 2021

Element Materials Technology to Expand its North American Presence with Avomeen Acquisition

Through the acquisition, Element will have access to Avomeen’s expertise in formulation chemistry, product manufacturing, extractables and leachables, and large molecule testing.

Element Materials Technology, a UK-based testing, inspection, and certification services company, announced on Feb. 3, 2021 that is acquiring Avomeen, an analytical testing services company located in the US, to expand its life sciences business unit in North America.

Through the acquisition, Element will have access to Avomeen’s expertise in formulation chemistry, product manufacturing, extractables and leachables, and large molecule testing, thus strengthening its technical range across several scientific disciplines, Element said in a company press release.

“We are thrilled to be joining the Element global family and combining our complementary capabilities to offer an even wider array of services and value to our clients,” said Mark Harvill, Avomeen CEO, in the press release. “Element’s focus on scientific excellence and quality, coupled with its partnership with clients and employees, aligns well with Avomeen’s values and what we will collectively continue to do as one company.”

“This is our third acquisition of 2021 and helps to build Element’s growing position in the life sciences sector, expanding our presence in the American pharmaceutical market,” added Jo Wetz, Element CEO, in the press release.

Source: Element


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.